Post TAVR ASA Monotherapy Consolidates

This meta-analysis to be published in J Am Cardiol supports the use of aspirin monotherapy (ASA) after transcatheter aortic valve replacement (TAVR).

The use of aspirin alone is associated to less bleeding without increased ischemic events such as strokes or mortality. 

The combined outcomes of four studies, including the recently published POPular TAVI (cohort A), have shown ASA alone is associated to a significantly lower risk of clinically relevant bleeding (HR 0.49; CI 95% 0.32-0.75), with a necessary number to treat of 19.

Antiaggregation type was not associated to mortality or risk of stroke. 

The American guidelines recommend dual antiaggregation therapy with aspirin and clopidogrel for 3 to 6 months after procedure in patients with no anticoagulation indication followed by ASA for life. 


Read also: Can Aspirin Use Be Interrupted After Angioplasty?


Similarly, the European guidelines also recommend dual antiaggregation therapy. 

These recommendations were made with valve endothelization in mind, to reduce thromboembolic events in the process.  However, there is no data to support this might be the case after TAVR. 

These guidelines were based on prior experience with coronary stents, quite a different procedure to TAVR.


Read also: Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events.


The 4 studies included 1086 patients (mean age 80) undergoing TAVR and followed up for mean 7 months.

Neither of these 4 studies have enough power to test for ischemic events separately, which is what motivated the present meta-analysis. 

There were no differences between dual antiaggregation and ASA monotherapy both in total mortality (HR 1.00; CI 95% 0.62-1.62) or stroke (HR 1.05; CI 95% 0.58-1.90).


Read also: Alternatives for Patients Allergic to Aspirin.


This meta-analysis contributes to the evidence, but not definitely, since the individual smaller studies could be biased. 

Original Title: Meta-analysis of aspirin monotherapy versus dual antiplatelet therapy after transcatheter aortic valve implantation.

Reference: Osman M et al. Am J Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...